

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 October 2022 (13.10.2022)



(10) International Publication Number
WO 2022/217155 A2

(51) International Patent Classification:
A61K 31/675 (2006.01)

(21) International Application Number:
PCT/US2022/024290

(22) International Filing Date:
11 April 2022 (11.04.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/173,354 09 April 2021 (09.04.2021) US
63/175,673 16 April 2021 (16.04.2021) US
63/210,246 14 June 2021 (14.06.2021) US
63/288,163 10 December 2021 (10.12.2021) US
63/298,836 12 January 2022 (12.01.2022) US

(71) Applicant: **EMORY UNIVERSITY** [US/US]; 1599
Clifton Road NE, 4th Floor, Atlanta, Georgia 30322 (US).


(72) Inventors: **SCHINAZI, Raymond**; 1000 Biscayne Boule-
vard, Apt. 4001, Miami, Florida 33132 (US). **AMBLARD,**

Franck; c/o Emory University, 1599 Clifton Road NE,
4th Floor, Atlanta, Georgia 30322 (US). **CHEN, Zhe**; c/o
Emory University, 1599 Clifton Road NE, 4th Floor, At-
lanta, Georgia 30322 (US). **ZANDI, Keivan**; c/o Emory
University, 1599 Clifton Road NE, 4th Floor, Atlanta, Geo-
rgia 30322 (US).

(74) Agent: **BRADIN, David**; 4141 Parklake Avenue, Suite
200, Raleigh, North Carolina 27612 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(54) Title: THIONUCLEOSIDES AS ANTIVIRAL AGENTS



IV	15	mg/kg				
ID	1	2	3	mean	SD	%CV
C_{max} ($\mu\text{g/mL}$)	18.6	20.5	20.9	20	1.23	6.14
T_{max} (hr)	0.5	0.5	0.5	0.5	0	0
AUC_{inf} ($\mu\text{g/mL}\cdot\text{hr}$)	175.2	160.3	205.6	180.4	23.1	12.8
$t_{1/2}$ (hr)	9.77	7.03	8.80	8.53	1.39	16.29
MRT _{0-∞} (hr)	13.39	10.09	12.66	12.05	1.73	14.37
CL/F _z (L/hr)/kg	0.086	0.094	0.073	0.084	0.010	12.35

Compound 8 concentrations were $> in vitro EC_{50}$ for $> 7 \text{ hr}$ after IV administration.

(57) Abstract: Compounds, compositions and methods for preventing, treating or curing a coronavirus infection in human subjects or other animal hosts. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1, OC43, and SARS-CoV-2. In another embodiment, the methods are used to treat a patient infected with a Flavivirus, Picornavirus, Togavirus, or Bunyavirus.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*